Gilead Q2 Revenue Beats by $400M, Raises 2026 Outlook on HIV Strength
GILD sits 27% above its 52-week low of $108.46.
Summary
Gilead delivered a strong Q2, with revenue of $7.8 billion beating the $7.4 billion consensus by 5.4%, driven by 12% growth in its core HIV franchise. The company swung to a loss due to R&D costs, with an adjusted loss per share of $6.75, narrower than the expected $7.24 loss, despite a $9.08 per share charge from recent acquisitions. Gilead raised the lower end of its full-year revenue guidance to $30.1 billion and significantly improved its adjusted loss per share outlook to a range of $0.65–$0.30, from a prior $1.65–$0.65 loss. Key products outperformed: Biktarvy sales rose 7% to $3.8 billion, Descovy jumped 48% to $967 million, and the new HIV prevention injection Yeztugo hit $232 million, exceeding forecasts and reinforcing confidence in reaching $1 billion for the year. Trodelvy sales grew 26% to $457 million, while liver disease portfolio revenue increased 10%. The results follow a series of transformative acquisitions and a $3 billion debt offering earlier this year, and the improved guidance signals that integration costs are being absorbed better than feared. Additionally, the California Supreme Court ordered dismissal of long-standing negligence claims, removing a legal overhang.
At the time of this announcement, GILD was trading at $137.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $167.9B. The 52-week trading range was $108.46 to $157.29. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.